These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 21543939)

  • 1. Clinical trials in recurrent ovarian cancer.
    Friedlander M; Trimble E; Tinker A; Alberts D; Avall-Lundqvist E; Brady M; Harter P; Pignata S; Pujade-Lauraine E; Sehouli J; Vergote I; Beale P; Bekkers R; Calvert P; Copeland L; Glasspool R; Gonzalez-Martin A; Katsaros D; Kim JW; Miller B; Provencher D; Rubinstein L; Atri M; Zeimet A; Bacon M; Kitchener H; Stuart GC;
    Int J Gynecol Cancer; 2011 May; 21(4):771-5. PubMed ID: 21543939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line therapy in ovarian cancer trials.
    Thigpen T; duBois A; McAlpine J; DiSaia P; Fujiwara K; Hoskins W; Kristensen G; Mannel R; Markman M; Pfisterer J; Quinn M; Reed N; Swart AM; Berek J; Colombo N; Freyer G; Gallardo D; Plante M; Poveda A; Rubinstein L; Bacon M; Kitchener H; Stuart GC;
    Int J Gynecol Cancer; 2011 May; 21(4):756-62. PubMed ID: 21543937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer.
    Bacon M; Kitchener H; Stuart GC; Vermorken JB;
    Int J Gynecol Cancer; 2011 May; 21(4):746-9. PubMed ID: 21543935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.
    Stuart GC; Kitchener H; Bacon M; duBois A; Friedlander M; Ledermann J; Marth C; Thigpen T; Trimble E; ;
    Int J Gynecol Cancer; 2011 May; 21(4):750-5. PubMed ID: 21543936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer.
    Joly F; Hilpert F; Okamoto A; Stuart G; Ochiai K; Friedlander M;
    Eur J Cancer; 2017 Jun; 78():133-138. PubMed ID: 28448857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.
    Herzog TJ; Ison G; Alvarez RD; Balasubramaniam S; Armstrong DK; Beaver JA; Ellis A; Tang S; Ford P; McKee A; Gershenson DM; Kim G; Monk BJ; Pazdur R; Coleman RL
    Gynecol Oncol; 2017 Oct; 147(1):3-10. PubMed ID: 28844539
    [No Abstract]   [Full Text] [Related]  

  • 7. Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.
    Bookman MA; Okamoto A; Stuart G; Yanaihara N; Aoki D; Bacon M; Fujiwara K; González-Martín A; Harter P; Kim JW; Ledermann J; Pujade-Lauraine E; Quinn M; Ochiai K;
    Ann Oncol; 2017 Nov; 28(suppl_8):viii30-viii35. PubMed ID: 29232472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice.
    González-Martín A
    Future Oncol; 2017 Oct; 13(23s):3-9. PubMed ID: 29020819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical cytoreduction in ovarian cancer.
    McCreath WA; Chi DS
    Oncology (Williston Park); 2004 May; 18(5):645-53, discussion 653-4, 656, 658. PubMed ID: 15209191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
    Tate Thigpen J
    Gynecol Oncol; 2015 Jan; 136(1):121-9. PubMed ID: 25455732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.
    Wilson MK; Pujade-Lauraine E; Aoki D; Mirza MR; Lorusso D; Oza AM; du Bois A; Vergote I; Reuss A; Bacon M; Friedlander M; Gallardo-Rincon D; Joly F; Chang SJ; Ferrero AM; Edmondson RJ; Wimberger P; Maenpaa J; Gaffney D; Zang R; Okamoto A; Stuart G; Ochiai K;
    Ann Oncol; 2017 Apr; 28(4):727-732. PubMed ID: 27993805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer.
    Ledermann JA; Raja FA
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S104-15. PubMed ID: 21943964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials and treatment of the elderly diagnosed with ovarian cancer.
    Freyer G; Tinker AV;
    Int J Gynecol Cancer; 2011 May; 21(4):776-81. PubMed ID: 21543940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The optimal time for surgery in women with serous ovarian cancer.
    Stewart JM; Tone AA; Jiang H; Bernardini MQ; Ferguson S; Laframboise S; Murphy KJ; Rosen B; May T
    Can J Surg; 2016 Aug; 59(4):223-32. PubMed ID: 27240134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
    Vergote I; Gonzalez-Martin A; Lorusso D; Gourley C; Mirza MR; Kurtz JE; Okamoto A; Moore K; Kridelka F; McNeish I; Reuss A; Votan B; du Bois A; Mahner S; Ray-Coquard I; Kohn EC; Berek JS; Tan DSP; Colombo N; Zang R; Concin N; O'Donnell D; Rauh-Hain A; Herrington CS; Marth C; Poveda A; Fujiwara K; Stuart GCE; Oza AM; Bookman MA;
    Lancet Oncol; 2022 Aug; 23(8):e374-e384. PubMed ID: 35901833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.
    Leary AF; Quinn M; Fujiwara K; Coleman RL; Kohn E; Sugiyama T; Glasspool R; Ray-Coquard I; Colombo N; Bacon M; Zeimet A; Westermann A; Gomez-Garcia E; Provencher D; Welch S; Small W; Millan D; Okamoto A; Stuart G; Ochiai K;
    Ann Oncol; 2017 Apr; 28(4):718-726. PubMed ID: 27993794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.
    Harrison ML; Gore ME; Spriggs D; Kaye S; Iasonos A; Hensley M; Aghajanian C; Venkatraman E; Sabbatini P
    Gynecol Oncol; 2007 Sep; 106(3):469-75. PubMed ID: 17614127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal management of recurrent ovarian cancer.
    Markman M
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S40-3. PubMed ID: 19955913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
    Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
    Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgery for recurrent ovarian cancer.
    Heitz F; du Bois A; Kurzeder C; Pfisterer J; Barinoff J; Grabowski J; Hilpert F; Mahner S; Harter P
    Womens Health (Lond); 2011 Sep; 7(5):529-35. PubMed ID: 21879821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.